Here are the S-3 shelf registrations from ImageneBio, Inc. (IMA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow IMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMA filings page.
ImageneBio, Inc. has filed a shelf registration that permits it to offer and sell up to $200,000,000 of common stock, preferred stock, debt securities and warrants over time. Within this shelf, the company has also put in place an at‑the‑market program to sell up to $17,000,000 of common stock through Jefferies LLC as sales agent. The company is a clinical‑stage biopharmaceutical developer focused on immunological, autoimmune and inflammatory diseases, led by its anti‑OX40 antibody olevaprubart (IMG‑007). Net proceeds from any sales will be used for general corporate purposes, including clinical trial and other R&D spending, working capital and administrative expenses.
ImageneBio, Inc. is registering for resale up to 5,770,335 shares of common stock on behalf of selling stockholders. These shares are issuable upon exercise of pre-funded warrants that were sold in an April 14, 2026 private placement for an aggregate purchase price of approximately $30.0 million at $5.199 per warrant with a $0.001 per share exercise price. The company will not receive proceeds from any resale of the shares, and will receive only the nominal exercise price if warrants are exercised for cash. As of July 15, 2026, 11,279,130 shares of common stock were outstanding. The pre-funded warrants are exercisable at any time, do not expire until exercised in full, and are subject to a beneficial ownership limitation not to exceed 19.99%. ImageneBio’s common stock trades on the Nasdaq Capital Market under the symbol IMA.